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Abstract  
Background 
 Most previous publications on AHF exploring the relation between admissions to 
hospital for heart failure (HF) and subsequent outcomes have focused only on those 
patients with HF coded as the primary discharge diagnosis, which might be only a 
minority of all patients. Failure to quantify the size of the problem is likely to lead to 
an under-estimate of the health economic impact of heart failure and under-provision 
of resources for its care.  
Methods & Results 
EHFS1 screened consecutive deaths and discharges during 2000-2001, to ascertain 
patients with known or suspected HF. Information on presenting symptoms and 
signs were gathered. Of all 10,701 patients, HF was considered to be the primary 
reason for admission in 4,234 (40%), secondary reason for admission if complicated 
or prolonged stay in further 1,772 (17%), and in 4, 695 (43%) it was uncertain that 
HF is actively contributing in index admission. 278 (16%) from secondary HF, 286 
(9%) from primary HF and 183 (4%) from uncertain group were died during index 
admission. Hazard ratio of death was 3.26 (P<0.001) in secondary, 1.72 (P<0.001) in 
primary as compare to uncertain group. Total death after 12 weeks of discharge were 
again higher in secondary HF, 389 (22%), 558 (13%) in primary and 412 (9%) in 
uncertain group. 
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Conclusion 
Heart failure at secondary position has very high mortality even most of HF 
registries and clinical trial reported patients on primary position only. Significant 
number of patients was died from that group where diagnosis of HF was uncertain. 
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Introduction 
Heart failure (HF) is a common reason for hospitalization and also commonly 
complicates hospitalization for other reasons.1 Indeed, about 80% of hospitalisations 
caused or complicated by heart failure will have another diagnosis in the primary 
position. Most patients with heart failure will have other medical problem many of 
which cause, contribute to, complicate or are complicated by heart failure.2, 3 Heart 
failure as a secondary diagnosis is important for several reasons.4  
• The diagnosis of heart failure is usually first made during a hospital 
admission and this will often be due to a precipitating cause such as an acute 
coronary syndrome, arrhythmia or infection.5  
• An acute medical problem that is complicated by heart failure might be more 
likely to lead to admission.  
• Although heart failure might not cause admission it might be the key illness 
that dictates the length of hospital stay and prognosis. 
• When heart failure is due to left ventricular systolic dysfunction (LVSD), it 
should usually be treated with disease modifying agents whether it is a 
primary or secondary diagnosis. Hospitalisation offers an opportunity to 
review and improve management, although sadly the reverse is often the case 
on general medical wards, although this may be improving with the 
introduction of cardiology-based heart failure ‘out-reach’ services for patients 
with heart failure on general medical or surgical wards. 
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Most previous audits, registries and publications reporting on deaths and discharges 
for heart failure focussed only on patients with heart failure as a primary discharge 
diagnosis; a small minority of all hospitalisations complicated by heart failure. 1, 6-8 
Little is known about the outcome of patients admitted for other reasons but in 
whom heart failure is either a secondary or incidental diagnosis. Moreover, it is 
likely that the diagnosis of heart failure is often overlooked during a hospital 
admission. Many patients are treated with and discharged on loop diuretics for no 
obvious reason other than symptoms and signs of congestion. Even if these patients 
do not have heart failure, it should be suspected and investigated, although this is 
often not the case.9   Failure to consider all admissions with suspected heart failure 
will lead to a serious under-estimate of the health economic impact of heart failure 
and under-provision of resources for its care. 
The Euro Heart Failure Survey 1 (EHFS-1) enrolled patients either discharged on 
loop diuretics or with a diagnosis of heart failure preceding, causing or complicating 
hospitalisation.4 We explored the nature and importance of heart failure as a 
secondary or incidental diagnosis in this data-set. 
Methods 
In the EHFS-1 consecutive deaths and discharges primarily from medical wards 
were screened over a 6 week period during 2000-2001 from 115 hospitals in 24 
countries belonging to the European Society of Cardiology, to identify patients with 
known or suspected HF.4 10 The design and implementation of the survey have been 
published in detail previously.11 Information was gathered from patients’ case notes 
to identify if the patient fulfilled one or more of the following inclusion criteria; the 
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criteria were deliberately set wide in order to capture as much relevant diagnostic 
and therapeutic activity as possible:4 
1. A diagnosis of heart failure on the index admission, irrespective of the 
primary reason for admission. 
2. A diagnosis of heart failure recorded in the hospital records at any time 
during the previous three years. 
3. Loop diuretics given in the 24 hours prior to death or at discharge, unless for 
renal failure.  
4. Administration of treatment for heart failure or major ventricular dysfunction 
within the 24 hours prior to death or discharge. Investigators especially 
reviewed the use of angiotensin converting enzyme inhibitors (ACE-I), beta 
blockers, mineralo-corticoid receptor antagonists (MRA), diuretics and 
digitalis compounds during this period to ascertain the reason for 
administration.  
 
Admissions were then classified by investigators, according to their personal 
opinion, as follows:- 
• Heart failure as the primary diagnosis 
• Heart failure as a secondary diagnosis, complicating or prolonging admission 
• Heart failure as an incidental finding or diagnostically uncertain 
 
Presentation, events contributing to this admission, cardiovascular investigations, 
comorbid illnesses and therapy were recorded. Deaths occurring during the index 
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hospital admission and deaths and readmissions up to 3 months after discharge were 
reported. 
Continuous data are summarized by the median (25th/75th centiles); categorical data 
by percentages. Prognostic models for all-cause mortality were developed using Cox 
regression.  The proportionality of hazards (PH) assumption was verified for all 
covariates using tests based on Schoenfeld residuals. 12, 13 There was no departure 
from the proportional hazard assumption for any covariate.  Cox metrics include the 
hazard ratio (HR), 95% confidence intervals (CIs) and pseudo r2 (the square of the 
correlation coefficient of the actual and predicted values of the dependent variable). 
This is a measure of goodness-of-fit.13 Prognostic models were developed using k-
fold cross-validation.14 This procedure splits the data randomly into k partitions.  For 
each partition, it fits the specified model using the other k-1 groups, and uses the 
resulting parameters to predict the dependent variable in the unused group.  We 
arbitrarily chose k as 25 (hence 25-fold cross-validation). Our group has used this 
approach before.15 We started with 50 variables and then selected nine variables that 
were significant in at least 70% of cross-validations for the final model to assess 
mortality during the index hospital admission.  
Kaplan-Meier curves constructed using the log-rank test was used to compare 
outcomes in groups during index admission. We used logistic regression to assess 
mortality and readmission within 12 weeks after discharge from index admission. An 
arbitrary level of 5% statistical significance (two-tailed) was assumed. The Stata 
statistical computer package was used to analyse the data. 
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Results 
Of 10,701 patients admitted with suspected HF, heart failure was considered to be 
the primary reason for admission in 4,234 (40%), the secondary (if HF complicated 
or prolonged hospital stay) in a further 1,772 (17%), and in 4,695 (43%) it was 
uncertain whether HF was actively contributing to the admission. The clinical 
characteristics of each group are shown in Table 1. Although there were statistical 
differences in age and sex amongst the three groups, these were small and of 
doubtful clinical relevance.  More patients with a primary diagnosis of HF were 
prescribed loop diuretics at admission and discharge (71% & 84%) but this was only 
slightly greater than amongst patients with an incidental or uncertain finding of HF 
(58% & 74% respectively) Table 1. Indeed, there were remarkably few substantial 
differences amongst the three groups of patients. More patients with a secondary 
diagnosis of heart failure had a primary diagnosis of ACS. More patients with a 
primary diagnosis of heart failure had a dilated cardiomyopathy.  
Patients with a primary or secondary diagnosis of HF exhibited broadly similar 
echocardiographic features although the prevalence and severity of abnormalities 
tended to be greater in those with a primary diagnosis. Patients with an incidental or 
uncertain diagnosis were less likely to have had an echocardiogram. This highlights 
an important point; surveys that include only patients with a confirmed diagnosis of 
heart failure are an unreliable source of data on the quality of diagnostic 
investigation. It is possible that a diagnosis of HF would have been confirmed in a 
substantial proportion of patients had adequate diagnostic investigation been 
conducted (Table 2). There was no substantial difference in laboratory investigations, 
although patients with an incidental or uncertain diagnosis of HF had, statistically, 
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better renal function. Most patients in all three groups had either cardiomegaly or 
signs of pulmonary congestion or both on their chest X-ray although the proportion 
was substantially greater in those with a primary or secondary diagnosis of heart 
failure (Table 2). 
During the index admission, 16% (290) of those with a secondary diagnosis of HF, 
7% (301) of those with a primary diagnosis of HF and 4% (189) of those in whom 
the diagnosis was uncertain died. The unadjusted Hazard ratios (HR) were 3.26 for 
secondary HF and 1.73 for primary HF compared to the group with an uncertain 
diagnosis (Table 3)(Figure 1). 
Worsening HF was the main factor contributing to death in those with a primary or 
secondary diagnosis of HF and for 18% of those in the uncertain group. Myocardial 
infarction contributed to death in 34% of deaths where HF was a secondary 
diagnosis but only 18% where HF was a primary diagnosis and 16% when the 
diagnosis of HF was uncertain (Table 3). Stroke was an important contributor to death 
amongst patients with an incidental diagnosis of HF. Length of stay was on average 
three days longer in patients who had a secondary diagnosis of HF compared to the 
other two groups. After adjusting for prognostic variables including male sex, MI 
during index admission, unstable angina during index admission, evidence of dilated 
cardiomyopathy, history of ventricular tachycardia or fibrillation, history of stroke 
and moderate to severe left ventricle dilatation present in our final model, the HR for 
death during the index admission was 3.45 (CI 2.29-5.22) for those with a secondary 
diagnosis of HF and 2.55 (CI 1.73 – 3.77) for those with a primary diagnosis of HF 
as compare to uncertain group(Table 4). Harrell’s C statistic was 0.72 for the overall 
model, suggesting moderate discrimination.  
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Drugs at discharge or within 24 hours before death are shown in Table 5. There were 
few substantial differences in prescription rates; only for digoxin was there a >20% 
difference in prescribing rates, with 48% of those assigned a primary diagnosis being 
prescribed digoxin versus 26% in those with an uncertain diagnosis. The absolute 
differences in prescribing rate of loop diuretics, ACE inhibitors and MRA were only 
10-20% higher in patients with a primary diagnosis compared to uncertain diagnosis 
of HF.  The proportion of patients prescribed beta blockers was similar in all three 
groups, although statistically lowest in those with a primary diagnosis of HF (Table 5).  
 
In the 12 weeks following discharge, 287 (7%) patients with a primary, 117 (8%) 
with a secondary and 238 (5%) with an incidental or uncertain diagnosis of HF died 
(Table 6). Worsening heart failure was the single most common reported reason for 
death in all three groups, contributing to 40%, 25% and 22% of post-discharge 
deaths for patients with a primary, secondary or uncertain diagnosis of heart failure. 
The odds ratio (OR) for death was 1.30 (CI 1.01-1.55) for a primary and 1.47 (CI 
1.16-1.85) for a secondary diagnosis compared to those with an incidental or 
uncertain diagnosis.  However, no significant difference in mortality was observed 
on multi-variable analysis. The area under receiver operator characteristics (ROC) 
curve was 0.55 for this model adjusted for all relevant variables, suggesting poor 
discrimination for post-discharge mortality.  
Re-admissions, all-cause, due to cardiovascular reasons or due to heart failure within 
12 weeks after discharge were more common in patients with a primary, compared to 
a secondary or incidental/uncertain HF diagnosis (Table 6). For the composite 
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outcome of cardiovascular re-admissions or death within 12 weeks after discharge, 
the OR was 1.49 (p-<0.001, CI 1.33-1.66) for those with a primary diagnosis and 
1.32 (P<0.001, CI 1.13-1.53) for those with a secondary diagnosis, compared to 
those with an incidental/uncertain diagnosis of HF. However, again these differences 
were not statistically significant in multi variable analysis. The area under ROC 
curve for this model was 0.58 suggesting poor discrimination. 
Discussion 
Despite limitations, research surveys and registries are a rich source of information 
on patients encountered in clinical practice that may often be excluded from clinical 
trials. Although some substantial differences were observed amongst patients with a 
primary, secondary or incidental/uncertain diagnosis of heart failure they were few; 
the three populations had greater similarities than differences. Importantly, the 
outcomes after discharge for each group were broadly similar in terms of mortality 
and re-admission, although statistical differences driven by large numbers were 
observed and the causes of readmission and death did differ amongst groups. Most 
readmissions were for CV reasons amongst patients with a primary or secondary 
diagnosis of HF but only two-thirds of those with an incidental/uncertain diagnosis. 
The characteristics of patients admitted to cardiology wards with a primary diagnosis 
of HF have been described in many surveys. However, the large proportions of 
patients with a primary diagnosis of HF who are admitted under the care of general 
physicians or geriatricians are much less well represented. Surveys such as this and 
some national registries 1 provide valuable insights into less “sanitized” populations 
with heart failure. However, it is difficult to avoid selection bias, which may have 
accounted for the relative youth in some countries, such as Germany, in this survey. 
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It is also likely that the EHFS-1 underestimated the full burden of patients with a 
secondary or uncertain diagnosis of heart failure. However, in the UK and many 
Scandinavian countries, EHFS-1 appeared to be successful in recruiting older 
patients with high rates of co-morbidity.  
The management and outcome of heart failure as a secondary diagnosis has been less 
well-described. This survey shows that ACS is most often the primary diagnosis 
when HF is considered an important secondary diagnosis and that these patients have 
a poor in-hospital prognosis although, for those that were discharged, subsequent 
outcome was no worse than for patients with a primary diagnosis of HF. 
The characteristics and outcome of the large number of patients in whom the 
diagnosis of HF is an incidental finding or diagnostically uncertain has rarely been 
described.  Cleland et al described the outcome of patients discharged on loop 
diuretics with or without a diagnosis of heart failure in a prospective survey over 18 
months from a single large hospital.9 Only a small proportion (~15%) of patients 
taking loop diuretics had a primary diagnosis of HF and less than half had a 
diagnosis of HF in any diagnostic position. However, patients receiving loop 
diuretics who had not been diagnostically labelled as HF had only a slightly lower 
mortality at two years compared to those who bore a diagnosis of HF. The study 
showed that few of these patients underwent diagnostic tests for HF. This diagnostic 
short-fall was also observed in EHFS-1. It is likely that this population contains a 
large proportion of patients with HF who have the characteristics and poor prognosis 
of other patients with HF but diluted by patients treated inappropriately with 
diuretics with a range of disease, some malign (eg:- stroke and cancer) and others 
relatively benign (eg:- COPD). Ignoring the diagnostic and therapeutic needs of this 
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group of patients is likely to be detrimental to their well-being and prognosis and 
seriously underestimates the resources required to manage HF and the economic 
burden it imposes.             
The diagnostic uncertainty of HF is a dilemma.16 Diagnostic tests such as 
echocardiography often require referral to the cardiology team which can be a barrier 
and rate-limiting step in many hospitals. Conventionally, this is considered part of 
the gold-standard for diagnosis although problems with reproducibility and 
interpretation skills have led to its central role being questioned.  Natriuretic peptides 
can be measured in routine blood samples regardless of who is caring for the patient. 
This greatly democratizes access to the diagnostic pathway in HF. However, 
although natriuretic peptides are useful to rule out HF they are considered prone to 
many false-positive results causing confusion for the inexperienced.16  Symptoms of 
HF are often mimicked by other conditions especially respiratory problems like 
chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD) and 
chest infections which may often co-exist with HF. Peripheral oedema in many older 
patients may also be due to conditions other than HF. In the presence of many 
comorbid illnesses, treating clinicians may be uncertain whether HF is contributing 
to the admission or not, even if these patients have a prior history of heart failure. 
These patients often receive therapy, such as diuretics, in an attempt to relieve 
symptoms and signs. Hospitalisation provides an opportunity to correct a patient’s 
diagnosis and rationalise and improve therapy even if HF is not the primary reason 
for admission.    
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1.1 Limitations 
EHFS1 was conducted at the turn of the century before the roles of beta blockers and 
cardiac resynchronization of therapy were well established. This will have 
influenced choice of therapy but should not have affected diagnosis. Natriuretic 
peptides were not recorded during admission. However, NT-proBNP was <125ng/L 
in only 47 of 2,368 patients in whom it was measured at the 12 week follow-up and 
75% had values >400ng/L.17 Median serum creatinine was 130umol/L indicating a 
substantial contribution of moderate renal dysfunction to increases in natriuretic 
peptides. About 25% were in atrial fibrillation, another cause for elevated plasma 
natriuretic peptide concentrations. However, even after controlling for renal 
dysfunction and atrial fibrillation, the increase in natriuretic peptides suggests that 
the great majority of patients had important cardiac dysfunction. Although, in 
surveys there are always chances of selection bias, EHFS1 was designed to try and 
avoid this as far as possible.11 In particular, the short but intense collection period 
(more than 10,000 patients enrolled over 6 weeks in115 hospitals), the attempt to 
recruit from medical wards and the high proportion of non-University hospitals 
should have reduced bias. However, without 100% ascertainment of suspected cases 
from a prospectively defined sampling frame it is impossible to be sure that no bias 
occurred. Indeed, it is likely that there was a bias towards sampling patients from 
cardiology wards and against patients in whom the diagnosis was in doubt.   
1.2 Conclusion 
Mortality is high even if heart failure is not main reason of admission but 
complicates another primary diagnosis. The high mortality may reflect the prognosis 
of the primary disease or other patient characteristics that impair the delivery of 
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effective care, including the place of care. Mortality amongst patients with an 
equivocal diagnosis of HF is also substantial and there appears to be a large 
diagnostic short-fall. Registries and surveys that do not include patients with HF as a 
contributory diagnosis may provide an over-optimistic view of prognosis and 
underestimate the resources required for diagnosis and effective management. 
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Figures 
 
 
 
 
Figure 1: Kaplan- Meier survival estimates during index admission 
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Tables 
 
Table 1: Clinical Characteristics 
     
 Primary Secondary Uncertain P--Value 
N = (%) 4,234 (40%) 1,772 (17%) 4,695 (44%)  
Age in Years 
(IQR) 
72 (63-80) 74 (65-80) 73 (64-80) <0.001 
Women 1,890 (45%) 837 (47%) 2,293 (49%) <0.001 
BMI (kg/m2) 26 (24-29) 26 (24-30) 27 (24-30) 0.1 
Loop diuretics 
prior to admission 
2,782 (71%) 859 (52%) 2,395 (58%) <0.001 
Loop diuretics at 
discharge  
3,532 (84%) 1,359 (77%) 3,455 (74%) <0.001 
MI during this 
admission 
215 (5%) 456 (26%) 413 (9%) <0.001 
MI (anytime) 1,421 (34%) 844 (48%) 1,746 (37%) <0.001 
UA this admission 417 (10%) 331 (19%) 724 (16%) <0.001 
UA (anytime) 902 (21%) 523 (30%) 1,199 (26%) <0.001 
h/o Angina 
(anytime) 
1,785 (43%) 961 (55%) 2,362 (51%) <0.001 
PCI  this 
admission  
82 (2%) 79 (4%) 203 (4%) <0.001 
PCI (anytime) 277 (7%) 147 (8%) 455 (10%) <0.001 
CABG  400 (9%) 199 (11%) 613 (13%) <0.001 
Heart Transplant ( 13 (<1%) 2 (<1%) 36 (<1%) <0.001 
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 Primary Secondary Uncertain P--Value 
LVAD implanted  23 (<1%) 8 (<1%) 9 (<1%) 0.02 
Evidence for DCM  755 (18%) 115 (7%) 336 (7%) <0.001 
Valve replacement  278 (7%) 70 (4%) 290 (6%) <0.001 
Valve repair   93 (2%) 28 (2%) 99 (2%) 0.28 
New onset or 
paroxysmal 
AF/SVT  
1,018 (24%) 482 (27%) 1,046 (22%) <0.001 
Chronic AF/SVT  1,228 (29%) 351 (20%) 903 (19%) <0.001 
VT/VF this 
admission 
239 (6%) 156 (9%) 143 (3%) <0.001 
VT/VF (anytime) 382 (9%) 196 (11%) 296 (6%) <0.001 
PPM  393 (9%) 139 (8%) 347 (7%) 0.004 
ICD implanted  70 (2%) 23 (1%) 60 (1%) 0.29 
h/o Hypertension  2,245 (53%) 982 (56%) 2,452 (53%) 0.06 
h/o Disabling 
stroke  
303 (7%) 198 (11%) 438 (9%) <0.001 
h/o Renal failure  882 (21%) 358 (20%) 593 (13%) <0.001 
Respiratory 
disease  
1,332 (32%) 653 (37%) 1,392 (24%) <0.001 
DM  1,193 (28%) 494 (28%) 1,220 (26%) 0.05 
h/o Pulmonary 
embolism  
129 (3%) 78 (4%) 145 (3%) 0.02 
HF; Heart failure, BMI; Body mass index, MI; Myocardial infarction, UA; Unstable 
angina, PCI; Percutaneous coronary intervention, CABG; Coronary artery bypass grafting, 
DCMP; Dilated cardiomyopathy, AF; Atrial fibrillation, SVT; Supraventricular 
tachycardia, VT; Ventricle tachycardia, VF; Ventricle fibrillation, TIA; Transient 
Ischaemic attack, DM; Diabetes Mellitus
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Table 2: Clinical investigations 
     
 Primary Secondary Uncertain P--Value 
N = (%) 4,234 (40%) 1,772 (17%) 4,695 (44%)  
Number with echo data 2,854 945 2,339  
Mild LVSD 451 (16%) 187 (20%) 469 (20%) <0.001 
Moderate / Severe LVSD 1,652 (58%) 489 (52%) 951 (41%) <0.001 
Moderate / Severe LV diastolic 
dysfunction  
415 (15%) 139 (15%) 266 (11%) <0.001 
LVEDD (cm) 5.8 (5-6.6) 5.4 (4.9-6.1) 5.3 (4.8-6) <0.001 
LVESD (cm) 4.5 (3.6-5.4) 4 (3.3-4.8) 3.9 (3.2-4.8) <0.001 
Moderate / Severe LA 
dilatation 
1,139 (40%) 265 (28%) 574 (25%) <0.001 
Moderate / Severe Mitral 
Stenosis 
111 (4%) 22 (2%) 73 (3%) 0.06 
Moderate / Severe Mitral 
Regurgitation 
1,080 (38%) 271 (29%) 574 (25%) <0.001 
Moderate / Severe Aortic 
stenosis 
275 (10%) 59 (6%) 163 (7%) <0.001 
Moderate / Severe Aortic 
regurgitation 
268 (9%) 64 (7%) 169 (9%) 0.004 
Moderate / Severe Right 
ventricle dysfunction 
262 (9%) 62 (7%) 93 (4%) <0.001 
Moderate / Severe Pulmonary 
hypertension 
674 (24%) 131 (14%) 266 (11%) <0.001 
 
Haemoglobin (g/dl)  12.9 (11.4-
14.2) 
12.7 (11.3-14.2) 12.9 (11.3- 
14.2) 
0.15 
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 Primary Secondary Uncertain P--Value 
Sodium (mmol/l) 139 (136-142) 139 (136-142) 139 (136-142) 0.06 
Potassium 4.3 (3.9- 4.7) 4.3 (3.9-4.7) 4.2 (3.9-4.6) 0.01 
Urea mmol/l 10.71 (7-17.6) 11.02 (7-17.85) 8.9 (6.2-14.5)` <0.001 
Creatinine (umol/l) 106 (88.4-135) 106 (88.4-141) 101 (83-126) <0.001 
Cholesterol most recent (mmol/l) 4.89 (3.9-5.8) 5.1 (4.1-5.93) 5.1 (4.3-5.92) <0.001 
Chest X-Ray: 
Cardiomegaly/Pulmonary 
congestion 
3,218 (86%) 1,205 (78%) 2,281 (61%) <0.001 
HF; Heart Failure, LVSD; Left ventricle systolic dysfunction, IQR; Interquartile Range, LVEDD; 
Left ventricle end diastolic diameter, LVESD; Left Ventricle end systolic diameter, LV; Left 
ventricle, LA; Left atrium. 
*Median and Interquartile range (IQR) are shown in continuous variables. 
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Table 3: Mortality & Length of stay (LOS) during index admission 
 Primary Secondary Uncertain  P--
Value 
N = (%) 4,234 (40%) 1,772 (17%) 4,695 (44%)  
Deaths  
 
301 (7%) 
 
290 (16%) 
 
189 (4%) <0.001 
Unadjusted HR (95% CI) 1.73 (1.43-2.08) 3.26 (2.70-3.93)   
Events Contributing to death (proportion deaths) 
MI 53 (18%) 100 (34%) 31 (16%) <0.001 
Worsening HF 239 (79%) 203 (70%) 35 (18%) <0.001 
Renal Failure 79 (26%) 76 (26%) 21 (11%) <0.001 
Ventricular Arrhythmia 42 (14%) 35 (12%) 13 (7%) <0.001 
Atrial Arrhythmia 35 (12%) 39 (13%) 8 (4%) <0.001 
Infection 87 (29%) 93 (32%) 57 (30%) <0.001 
Stroke 6 (2%) 31 (11%) 32 (17%) <0.001 
Cancer 10 (3%) 22 (8%) 30 (16%) <0.001 
Other 43 (14%) 76 (26%) 72 (38%) <0.001 
Median LOS during index 
admission in days (IQR) 
8 (4-14) 11 (8-17) 8 (4-13) <0.001 
 
 
HF; Heart Failure, HR; Hazard ration, CI; Confidence interval, MI; Myocardial Infarction, IQR; 
Interquartile range, LOS; Length of stay 
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Table 4: Multi variable Cox Model Showing Variables Associated with Death during the Index Admission 
 
 
Hazard Ratio Standard 
error 
Z Statistics P Value 95% 
Confidence 
interval 
Primary HF 2.55 0.50 4.74 <0.001 1.73 - 3.76 
Secondary HF 3.45 0.72 5.90 <0.001 2.28 – 5.22 
Male 0.81 0.11 -1.55 0.12 0.62 – 1.05 
MI during index 
admission 
1.79 0.30 3.45 0.001 1.29 – 2.50 
Admission for UA 
during this 
admission 
0.96 0.20 -0.22 0.83 0.64 – 1.42 
Evidence for 
DCMP  
1.19 0.23 0.91 0.36 0.82 – 1.73 
VT/VF diagnosed  1.78 0.29 3.54 <0.001 1.29 – 2.45 
Disabling stroke  1.47 0.29 1.89 0.06 0.98 – 2.19 
Moderate / Severe 
LV dilatation 
0.94 0.15 -0.37 0.71 0.69 – 1.28 
Creatinine (umol/l) 1.07 0.001 4.70 <0.001 1.04 – 1.09 
 
HF; Heart failure, MI; Myocardial Infarction, UA; Unstable angina, DCMP; Dilated 
cardiomyopathy, VT; Ventricle tachycardia, VF; Ventricle fibrillation, LV; Left ventricle, 
umol/l; Micro mole / per liter 
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Table 5: Drugs at discharge 
 Primary Secondary Uncertain P—Value 
 4,234 (40%) 1,772 (17%) 4,695 (43%)  
Spironolactone 1,357 (32%) 300 (17%) 540 (12%) <0.001 
Furosemide 3,489 (82%) 1,335 (75%) 3,327 (71%) <0.001 
Bumetanide 126 (3%) 4 (2%) 110 (2%) 0.16 
Torasemide 163 (4%) 64 (4%) 140 (3%) 0.07 
Metolazone 77 (2%) 19 (1%) 21 (<1%) <0.001 
Thiazide diuretic 508 (12%) 163 (9%) 397 (8%) <0.001 
ACEI 2,964 (70%) 1,069 (60%) 2,577 (55%) <0.001 
ARB 218 (5%) 50 (3%) 213 (5%) <0.001 
Nitrate 1,872 (44%) 817 (46%) 2,005 (43%) 0.04 
Calcium channel blockers 773 (18%) 361 (20%) 1,131 (24%) <0.001 
Beta blockers  1,459 (34%) 695 (39%) 1,790 (38%) <0.001 
Digoxin 2,036 (48%) 562 (32%) 1,227 (26%) <0.001 
Antiarrhythmic drugs 703 (17%) 272 (15%) 599 (13%) <0.001 
Lipid lowering drugs 747 (18%) 343 (19%) 1,097 (23%) <0.001 
HF; Heart Failure, ACI; Angiotensin converting enzyme inhibitor, ARB; Angiotensin receptor 
blockers 
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Table 6: Mortality & Readmission within 12 Weeks after discharge 
     
 Primary Secondary  Uncertain  P--Value 
Deaths 
 
287  
(7%) 
 
117  
(8%) 
 
229  
(7%) 
0.001 
Unadjusted OR (95% CI) 1.30  
(1.01-1.55) 
1.47  
(1.16-1.85) 
  
Events contributing to death 
(proportion deaths) 
    
MI 27  
(9%) 
10  
(9%) 
25  
(11%) 
0.88 
Worsening HF 114  
(40%) 
29  
(25%) 
50  
(22%) 
<0.001 
Renal Failure 23  
(8%) 
12  
(10%) 
12  
(6%) 
0.02 
Ventricular Arrhythmia 22  
(8%) 
2  
(2%) 
7  
(3%) 
0.002 
Atrial Arrhythmia 8  
(3%) 
4  
(3%) 
8  
(3%) 
0.87 
Infection 24  
(8%) 
17  
(15%) 
40  
(17%) 
0.16 
Stroke 19  
(7%) 
9  
(8%) 
19  
(8%) 
0.87 
Death caused by cancer 16  
(6%) 
9  
(8%) 
28  
(12%) 
0.27 
Other events contributing to 
death 
43  
(15%) 
30  
(26%) 
63  
(28%) 
0.07 
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 Primary Secondary  Uncertain  P--Value 
Readmission within 12 weeks 
after discharge 
    
All cause 961  
(23%) 
 
344  
(19%) 
 
980  
(21%) 
0.01 
 OR 1.12  
(CI 1.01-1.22) 
OR 0.91 
(CI 0.80 – 1.04) 
  
Due to cardiovascular cause 772  
(18%) 
 
240  
(14%) 
 
580  
(13%) 
<0.001 
 OR 2.92  
(CI 2.38-3.58) 
OR 1.61 
(CI 1.24-2.09) 
  
Due to Heart Failure 517  
(12%) 
 
134  
(8%) 
 
240  
(5%) 
<0.001 
 OR 3.8 
(CI 3.03-4.46) 
OR 1.99 
(CI 1.53-2.59) 
  
 
HF; heart failure, MI; Myocardial infarction, OR; Odd ratio, CI; Confidence interval 
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